06826 HAOHAI BIOTEC
- 40.950
- +0.800+1.99%
HAOHAI BIOTEC News
HAOHAI BIOTEC To Go Ex-Dividend On June 6th, 2024 With 1.10175 HKD Dividend Per Share And 0.4 Stock Dividend Per Share
April 27th - $HAOHAI BIOTEC(06826.HK)$ is trading ex-dividend on June 6th, 2024. Shareholders of record on June 7th, 2024 will receive 1.10175 HKD dividend per share and 0.4 stock dividend per sha
Haohai Biotechnology (06826) will pay a final dividend of 1 yuan per share on July 19
Haohai Biotechnology (06826) issued an announcement that it will be distributed on July 19, 2024 until 2024 until 2023...
Haohai Biotechnology (06826.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Haohai Biotechnology (06826.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on April 29, 2024 (Monday) to review and approve (including) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
昊海生物科技：董事會會議召開日期
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
HAOHAI BIOTEC: ANNUAL REPORT 2023
Haohai Biotechnology (06826) did not implement share repurchases in March and has repurchased a total of about 1.346,800 A-shares
According to the Zhitong Finance App, Haohai Biotechnology (06826) announced the progress of repurchasing the company's A shares through centralized bidding transactions. In March 2024, the company did not implement a share repurchase. As of March 31, 2024, the company has repurchased approximately 1,346,800 A-shares of the company through centralized bidding transactions, accounting for 0.80% of the company's total share capital. The highest transaction price was 113.50 yuan/share, the lowest transaction price was 84.26 yuan/share, and the total transaction amount was approximately RMB 140 million (excluding transaction fees such as stamp duty and transaction commissions).
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
Haohai Biotechnology (06826): 526,400 A-share restricted shares will be listed and circulated on April 1
Haohai Biotechnology (06826) issued an announcement regarding the first grant of the 2021 A-share Restricted Stock Incentive Plan to the Ministry...
Haohai Biotech's hyaluronic acid is still a good business, but ophthalmology is more complicated
“Investor Network” Cai Jun's hyaluronic acid competition among the Three Musketeers of Medicine and Aesthetics is getting hotter and hotter. Recently, Haohai Biotech (688366.SH, hereinafter referred to as the “Company”) and Aimeike released their 2023 Annual Report. During the reporting period, the company's operating income and net profit attributable to shareholders of listed companies were 2,654 million yuan and 416 million yuan respectively, up 24.59% and 130.58% year-on-year respectively. In the same period, Aimeike's operating revenue and net profit attributable to shareholders of listed companies were 2.87 billion yuan and 1,858 billion yuan respectively, up 47.99% and 47.08% year-on-year respectively. It should be pointed out that doctors who love American customers
Haohai Biotechnology (06826) issued 526,400 A-shares under the Restricted Stock Incentive Plan
Haohai Biotechnology (06826) issued an announcement on March 26, 2024, based on restricted stocks in 2021...
Haohai Biotechnology (06826.HK) cancelled 3.296,500 repurchased shares on March 19
Gelonghui March 19 | Haohai Biotechnology (06826.HK) issued an announcement to cancel 3.296,500 repurchased shares on March 19, 2024.
Haohai Biotech: 679,300 restricted shares were vested
Haohai Biotechnology (06826) issued an announcement. On March 18, 2024, the company held the 21st meeting of the 5th board of directors to review the “Proposal on Granting Part 2 of the Company's 2021 A-share Restricted Stock Incentive Plan for the First Time to Meet the Eligibility Requirements”. According to the authorization of the company's first extraordinary general meeting of shareholders in 2022, the first A-share class shareholders' meeting in 2022, and the first H-share class shareholders' meeting in 2022, the board of directors believes that the vesting conditions stipulated in the company's 2021 A share restricted stock incentive plan for the first time to grant a second vesting period have been fulfilled, and the current number of attributable shares
Haohai Biotechnology (06826): 679,300 restricted shares were vested
Zhitong Finance App News, Haohai Biotechnology (06826) issued an announcement. On March 18, 2024, the company held the 21st meeting of the 5th board of directors to review the “Proposal on Granting Part 2 of the Company's 2021 A-share Restricted Stock Incentive Plan for the First Time to Meet the Vesting Conditions”. According to the authorization of the company's first extraordinary general meeting of shareholders in 2022, the first A-share class shareholders' meeting in 2022, and the first H-share class shareholders' meeting in 2022, the board of directors believes that the vesting conditions stipulated in the company's 2021 A-share restricted stock incentive plan for the first time granted a second vesting period have already been met
Shanghai Haohai Biological Technology (HKG:6826) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. However, our analysis sugge
Haohai Biotech (688366.SH): Currently, customized products account for the largest share of revenue from first-generation hyaluronic acid Haiwei
Gelonghui March 14 | Haohai Biotech (688366.SH) disclosed an investor relations activity record table showing that the medical and aesthetic market is rapidly updating and iterating, and beauty seekers are also very enthusiastic about new brands, so some downstream institutions are considering the cost side and are beginning to generate some product customization requirements. Currently, the largest share of the company's customized product revenue is Haiwei, the company's first-generation hyaluronic acid. The main reason is that Haiwei has been on the market for more than ten years, the quality of its products has been fully verified, and the terminal price is also very friendly.
Haohai Biotech (688366.SH): Fourth-generation organic crosslinked hyaluronic acid products have completed clinical trials in China
Gelonghui March 14 丨 Haohai Biotech (688366.SH) disclosed an investor relations activity record sheet showing that the company's fourth-generation organic crosslinked hyaluronic acid products have completed domestic clinical trials and are currently in the late stages of registration review. The company's medical and aesthetic product pipeline is, on the one hand, filled with hyaluronic acid. On the other hand, the company is also actively exploring the clinical application of various product combinations. At the same time, the company also has a layout in the water light category and botulinum toxin products. Furthermore, the company made a key layout in medical and aesthetic energy source equipment through the acquisition of European Huameke. In the medical and aesthetic field, the company has now formed a cover for hyaluronic acid and cuticle repair
Positive Earnings Growth Hasn't Been Enough to Get Shanghai Haohai Biological Technology (HKG:6826) Shareholders a Favorable Return Over the Last Three Years
Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) shareholders should be happy to see the share price up 16% in the last month. If you look at the last three years, the stock price is down
Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5%
Shanghai Haohai Biological Technology's (HKG:6826, SHA:688366) attributable profit surged to 416.1 million yuan, or 2.44 yuan per share, in 2023 from 180.5 million yuan, or 1.04 yuan per share, in 202
Changes in Hong Kong stocks | Haohai Biotech (06826) rose more than 7%, net profit increased 1.3 times year-on-year last year, hyaluronic acid continued to increase
Haohai Biotechnology (06826) rose more than 7%. As of press release, it had risen 7.2% to HK$40.2, with a turnover of HK$5.797,700.
Analysis
Price Target
No Data
